{
    "ticker": "IDNA",
    "name": "IDNA, Inc.",
    "description": "IDNA, Inc. is a biotechnology company specializing in the development of innovative therapies for rare genetic disorders. Founded in 2015, IDNA is dedicated to advancing the understanding and treatment of conditions caused by genetic mutations. The company leverages cutting-edge genomic technologies and a robust pipeline of product candidates to address unmet medical needs in the field of rare diseases. IDNA's lead product candidate is designed to target specific genetic anomalies, aiming to restore normal function and improve patient outcomes. The company collaborates with leading research institutions and has established partnerships with other biotech firms to enhance its research capabilities. IDNA is committed to patient-centric approaches and actively involves patient advocacy groups in its clinical trials. The company's mission is to transform lives through science by delivering safe and effective therapies that can significantly improve the quality of life for patients suffering from genetic disorders.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2015",
    "website": "https://www.idna.com",
    "ceo": "Dr. Emily Carter",
    "social_media": {
        "twitter": "https://twitter.com/idnainc",
        "linkedin": "https://www.linkedin.com/company/idna-inc"
    },
    "investor_relations": "https://ir.idna.com",
    "key_executives": [
        {
            "name": "Dr. Emily Carter",
            "position": "CEO"
        },
        {
            "name": "John Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IDN-101",
                "IDN-202"
            ]
        }
    ],
    "seo": {
        "meta_title": "IDNA, Inc. | Innovating Genetic Disorder Therapies",
        "meta_description": "IDNA, Inc. is committed to developing breakthrough therapies for rare genetic disorders. Explore our innovative approach to biotechnology and patient care.",
        "keywords": [
            "IDNA",
            "Biotechnology",
            "Genetic Disorders",
            "Therapeutics",
            "Rare Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does IDNA specialize in?",
            "answer": "IDNA specializes in developing therapies for rare genetic disorders."
        },
        {
            "question": "Who is the CEO of IDNA?",
            "answer": "Dr. Emily Carter is the CEO of IDNA, Inc."
        },
        {
            "question": "Where is IDNA headquartered?",
            "answer": "IDNA is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are IDNA's main products?",
            "answer": "IDNA's main products include IDN-101 and IDN-202."
        },
        {
            "question": "When was IDNA founded?",
            "answer": "IDNA was founded in 2015."
        }
    ],
    "competitors": [
        "VRTX",
        "SGEN",
        "PTCT",
        "IBRX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BMY"
    ]
}